The field of cancer immunotherapy has been re-energized by the application of chimeric
antigen receptor (CAR) T cell therapy in cancers. These CAR T cells are engineered to …

This review is focused on different subsets of T cells: CD4 and CD8, memory and effector
functions, and their role in CAR-T therapy––a cellular adoptive immunotherapy with T cells …

The immunosuppressive tumor microenvironment (TME) represents a major barrier for
effective immunotherapy. Tumor-associated macrophages (TAMs) are highly heterogeneous …

Therapies with novel mechanisms of action are needed for multiple myeloma (MM). B-cell
maturation antigen (BCMA) is expressed in most cases of MM. We conducted the first-in …

B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …

Despite being empirically designed based on a simple understanding of TCR signaling, T
cells engineered with chimeric antigen receptors (CARs) have been remarkably successful …

Chimeric antigen receptors (CAR) are synthetic receptors that target T cells to cell-surface
antigens and augment T-cell function and persistence. Mesothelin is a cell-surface antigen …

Adoptive cell therapy has emerged as a powerful treatment for advanced cancers resistant
to conventional agents. Most notable are the remarkable responses seen in patients …

Investigators developed chimeric antigen receptors (CAR s) for expression on T cells more
than 25 years ago. When the CAR is derived from an antibody, the resultant cell should …

Limited clinical benefit has been demonstrated for chimeric antigen receptor (CAR) therapy
of solid tumors, but coengineering strategies to generate so-called fourth-generation (4G) …